Appeal No. 2007-0091
Application No. 09/765,491
BACKGROUND
The specification describes “[m]ethods for treating diseases or
disorders of the skin which are characterized by angiogenesis . . . using
curcumin.” (Specification 3.) “Curcumin . . . and certain of its analogs,
together termed curcuminoids, are well known natural products. . . .
Curcumin is a yellow pigment found in the rhizome of Curcuma longa, the
source of the spice turmeric.” (Id. at 8.)
The specification states that “curcumin inhibits basic fibroblast
growth factor (bFGF)-induced proliferation . . . in vitro and angiogenesis in
vivo.” (Id. at 15.) “Based on the results . . . with curcumin, it has been
determined that other angiogenesis inhibitors can also be used to treat these
skin disorders.” (Id. at 3.)
DISCUSSION
1. CLAIMS
Claims 4-6, 10-12, and 17-19 are pending and on appeal. The claims
have not been argued separately so the claims subject to each rejection will
stand or fall together. 37 CFR § 41.37(c)(1)(vii). Claims 4, 10, and 17 are
the only independent claims and read as follows:
4. A method for inhibiting symptoms associated with angiogenesis
in the treatment of skin disorders selected from the group consisting of
lymphangiogenesis, Sturge-Weber syndrome, verruca vulgaris, tuberous
sclerosis, venous ulcers, molluscum contagious, seborrheic keratosis, and
actinic keratosis comprising administering to the individual in need of
treatment thereof an angiogenesis inhibitor wherein the angiogenesis
inhibitor is selected from the group consisting of collagenase inhibitors,
angiogenic fumagillin derivatives, 2,5-diaryltetrahydrofurans,
aminophenylphosphonic acid compounds, 3-substituted oxindole
derivatives, thalidomides, penicillamine and IL12 in an amount effective to
inhibit angiogenesis.
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: September 9, 2013